Boston Scientific Corporation (NYSE:BSX)‘s stock had its “hold” rating restated by equities researchers at Jefferies Group LLC in a research report issued on Thursday.

The analysts wrote, “We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787.””

Several other equities research analysts have also commented on the stock. Zacks Investment Research lowered shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. UBS AG reaffirmed a “buy” rating and issued a $31.00 price target (up from $30.00) on shares of Boston Scientific Corporation in a report on Tuesday, August 1st. BidaskClub lowered shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $30.00 price target on shares of Boston Scientific Corporation in a report on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $29.88.

Shares of Boston Scientific Corporation (NYSE:BSX) traded up 1.81% during trading on Thursday, reaching $28.73. The company had a trading volume of 2,396,584 shares. The company’s 50 day moving average is $27.01 and its 200-day moving average is $26.34. The stock has a market capitalization of $39.42 billion, a price-to-earnings ratio of 51.40 and a beta of 1.09. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $28.74.

Boston Scientific Corporation (NYSE:BSX) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.01. The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.27 earnings per share. On average, equities research analysts anticipate that Boston Scientific Corporation will post $1.26 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/07/boston-scientific-corporation-bsx-stock-rating-reaffirmed-by-jefferies-group-llc.html.

In related news, EVP Timothy A. Pratt sold 10,104 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $27.46, for a total transaction of $277,455.84. Following the completion of the transaction, the executive vice president now owns 185,742 shares in the company, valued at approximately $5,100,475.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP John Bradley Sorenson sold 2,100 shares of the company’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $27.15, for a total transaction of $57,015.00. Following the transaction, the senior vice president now owns 18,880 shares of the company’s stock, valued at approximately $512,592. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 288,819 shares of company stock valued at $7,892,130. Insiders own 0.74% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BSX. BlackRock Inc. raised its position in shares of Boston Scientific Corporation by 2,181.6% during the 1st quarter. BlackRock Inc. now owns 95,744,545 shares of the medical equipment provider’s stock worth $2,381,169,000 after purchasing an additional 91,548,235 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Boston Scientific Corporation by 22,491.6% during the 2nd quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock worth $1,077,270,000 after purchasing an additional 38,690,577 shares during the last quarter. FMR LLC raised its position in shares of Boston Scientific Corporation by 7.6% during the 1st quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock worth $4,593,698,000 after purchasing an additional 13,105,596 shares during the last quarter. Jennison Associates LLC raised its position in shares of Boston Scientific Corporation by 405.3% during the 2nd quarter. Jennison Associates LLC now owns 10,639,290 shares of the medical equipment provider’s stock worth $294,921,000 after purchasing an additional 8,533,655 shares during the last quarter. Finally, MARSHALL WACE ASIA Ltd acquired a new position in shares of Boston Scientific Corporation during the 1st quarter worth about $149,859,000. Hedge funds and other institutional investors own 90.52% of the company’s stock.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.